2335--C

2013-2014 Regular Sessions

IN ASSEMBLY

January 14, 2013

- Introduced by M. of A. RODRIGUEZ, ABINANTI, GUNTHER, BRONSON, RIVERA, CYMBROWITZ, BROOK-KRASNY, GOTTFRIED, JACOBS, SCHIMEL, ARROYO, JAFFEE, SCARBOROUGH, WEPRIN, DINOWITZ, CAMARA, GOLDFEDER, ROSENTHAL, PERRY, COLTON, HOOPER, ZEBROWSKI, SIMANOWITZ, MAGNARELLI, BENEDETTO, ABBATE, TITONE, ROBERTS, CRESPO, QUART, WEISENBERG, CAHILL, MILLMAN, AUBRY, SKOUFIS, OTIS, RAIA, PAULIN, MONTESANO -- Multi-Sponsored by -- M. of CROUCH, DUPREY, GLICK, HEASTIE, LENTOL, Α. BRENNAN, CLARK, COOK, LUPARDO, MAGEE, PEOPLES-STOKES, RUSSELL, SKARTADOS, SWEENEY, THIELE, TITUS, WEINSTEIN, WRIGHT -- read once and referred to the Committee on Health -- reported and referred to the Committee on Codes -- reported and referred to the Committee on Ways and Means -- committee discharged, bill amended, ordered reprinted as amended and recommitted said committee -- again reported from said committee with amendto ments, ordered reprinted as amended and recommitted to said committee -- recommitted to the Committee on Health in accordance with Assembly Rule 3, sec. 2 -- reported and referred to the Committee on Codes _ _ _ reported and referred to the Committee on Ways and Means -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
- AN ACT to amend the social services law and the public health law, in relation to prescription drugs in Medicaid managed care programs; and to repeal certain provisions of the social services law, relating to payments for prescription drugs

THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

1 Section 1. The social services law is amended by adding a new section 2 365-i to read as follows:

3 S 365-I. PRESCRIPTION DRUGS IN MEDICAID MANAGED CARE PROGRAMS. 1. 4 DEFINITIONS. AS USED IN THIS SECTION, UNLESS THE CONTEXT CLEARLY 5 REQUIRES OTHERWISE:

EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
[] is old law to be omitted.

LBD05620-06-4

16

17

1 (A) "ARTICLE" MEANS TITLE ELEVEN OF ARTICLE FIVE OF THIS CHAPTER WITH 2 RESPECT TO THE MEDICAL ASSISTANCE PROGRAM, TITLE ELEVEN-D OF ARTICLE 3 FIVE OF THIS CHAPTER WITH RESPECT TO THE FAMILY HEALTH PLUS PROGRAM, AND 4 TITLE ONE-A OF ARTICLE TWENTY-FIVE OF THE PUBLIC HEALTH LAW WITH RESPECT 5 TO THE CHILD HEALTH INSURANCE PROGRAM.

6 (B) "CLINICAL DRUG REVIEW PROGRAM" MEANS THE CLINICAL DRUG REVIEW 7 PROGRAM UNDER SECTION TWO HUNDRED SEVENTY-FOUR OF THE PUBLIC HEALTH LAW. 8 (C) "EMERGENCY CONDITION" MEANS A MEDICAL OR BEHAVIORAL CONDITION AS 9 DETERMINED BY THE PRESCRIBER OR PHARMACIST, THE ONSET OF WHICH IS 10 SUDDEN, THAT MANIFESTS ITSELF BY SYMPTOMS OF SUFFICIENT SEVERITY, 11 INCLUDING SEVERE PAIN, AND FOR WHICH DELAY IN BEGINNING TREATMENT 12 PRESCRIBED BY THE PATIENT'S HEALTH CARE PRACTITIONER WOULD RESULT IN:

13 (I) PLACING THE HEALTH OR SAFETY OF THE PERSON AFFLICTED WITH SUCH 14 CONDITION OR OTHER PERSON OR PERSONS IN SERIOUS JEOPARDY;

15 (II) SERIOUS IMPAIRMENT TO SUCH PERSON'S BODILY FUNCTIONS;

(III) SERIOUS DYSFUNCTION OF ANY BODILY ORGAN OR PART OF SUCH PERSON;

(IV) SERIOUS DISFIGUREMENT OF SUCH PERSON; OR

18 (V) SEVERE DISCOMFORT.

19 (D) "MANAGED CARE PROVIDER" MEANS A MANAGED CARE PROVIDER UNDER SECTION THREE HUNDRED SIXTY-FOUR-J OF THIS TITLE, A MANAGED LONG TERM 20 21 PLAN OR OTHER CARE COORDINATION MODEL UNDER SECTION FORTY-FOUR CARE 22 HUNDRED THREE-F OF THE PUBLIC HEALTH LAW, A FAMILY HEALTH INSURANCE PLAN UNDER SECTION THREE HUNDRED SIXTY-NINE-EE OF THIS ARTICLE (FAMILY HEALTH 23 24 PLUS PROGRAM), AN APPROVED ORGANIZATION UNDER TITLE ONE-A OF ARTICLE 25 TWENTY-FIVE OF THE PUBLIC HEALTH LAW (CHILD HEALTH INSURANCE PROGRAM), 26 OR ANY OTHER ENTITY THAT PROVIDES OR ARRANGES FOR THE PROVISION OF 27 MEDICAL ASSISTANCE SERVICES AND SUPPLIES TO PARTICIPANTS DIRECTLY OR INDIRECTLY (INCLUDING BY REFERRAL), INCLUDING CASE MANAGEMENT, INCLUDING 28 29 THE MANAGED CARE PROVIDER'S AUTHORIZED AGENTS.

30 (E) "NON-PREFERRED DRUG" MEANS A PRESCRIPTION DRUG THAT REQUIRES PRIOR 31 AUTHORIZATION UNDER THE PARTICIPANT'S MANAGED CARE PROVIDER.

(F) "PARTICIPANT" MEANS A MEDICAL ASSISTANCE RECIPIENT WHO RECEIVES,
 IS REQUIRED TO RECEIVE OR ELECTS TO RECEIVE HIS OR HER MEDICAL ASSIST ANCE SERVICES FROM A MANAGED CARE PROVIDER.

(G) "PREFERRED DRUG" MEANS A PRESCRIPTION DRUG THAT IS NOT A NON-PRE FERRED DRUG UNDER THE PATIENT'S MANAGED CARE PROVIDER. "PREFERRED DRUG
 LIST" MEANS A LIST OF A MANAGED CARE PROVIDER'S PREFERRED DRUGS.

(H) "PREFERRED DRUG PROGRAM" MEANS THE PREFERRED DRUG PROGRAM ESTAB LISHED UNDER SECTION TWO HUNDRED SEVENTY-TWO OF THE PUBLIC HEALTH LAW.

40 (I) "PRESCRIBER" MEANS A HEALTH CARE PROFESSIONAL AUTHORIZED TO 41 PRESCRIBE PRESCRIPTION DRUGS FOR A PARTICIPANT OF THE MANAGED CARE 42 PROVIDER, ACTING WITHIN HIS OR HER LAWFUL SCOPE OF PRACTICE.

43 (J) "PRESCRIPTION DRUG" OR "DRUG" MEANS A DRUG DEFINED IN SUBDIVISION SEVEN OF SECTION SIXTY-EIGHT HUNDRED TWO OF THE EDUCATION LAW, FOR WHICH 44 45 A PRESCRIPTION IS REQUIRED UNDER THE FEDERAL FOOD, DRUG AND COSMETIC ACT. ANY DRUG THAT DOES NOT REQUIRE A PRESCRIPTION UNDER SUCH ACT, BUT 46 47 WHICH WOULD OTHERWISE BE ELIGIBLE FOR REIMBURSEMENT UNDER THIS ARTICLE 48 WHEN ORDERED BY A PRESCRIBER AND THE PRESCRIPTION IS SUBJECT TO THE 49 APPLICABLE PROVISIONS OF THIS ARTICLE AND PARAGRAPH (A) OF SUBDIVISION 50 FOUR OF SECTION THREE HUNDRED SIXTY-FIVE-A OF THIS TITLE.

51 (K) "PRIOR AUTHORIZATION" MEANS A PROCESS REQUIRING THE PRESCRIBER OR 52 THE DISPENSER TO VERIFY WITH THE PARTICIPANT'S MANAGED CARE PROVIDER 53 THAT THE DRUG IS APPROPRIATE FOR THE NEEDS OF THE SPECIFIC PATIENT.

54 (L) "QUALIFIED PRESCRIPTION DRUG SYSTEM" OR "SYSTEM" MEANS A PROCESS 55 UNDER THIS SECTION, APPROVED BY THE COMMISSIONER, THROUGH WHICH A 1 MANAGED CARE PROVIDER APPROVES PAYMENT FOR A NON-PREFERRED DRUG FOR A 2 PARTICIPANT BASED ON PRIOR AUTHORIZATION.

3 2. PAYMENT FOR PRESCRIPTION DRUGS UNDER CAPITATION. (A) PAYMENT FOR 4 PRESCRIPTION DRUGS SHALL BE INCLUDED IN THE CAPITATION PAYMENTS FOR 5 SERVICES OR SUPPLIES PROVIDED TO A MANAGED CARE PROVIDER'S PARTICIPANTS, 6 THAT THE MANAGED CARE PROVIDER PAYS FOR PRESCRIPTION DRUGS PROVIDED 7 UNDER A OUALIFIED PRESCRIPTION DRUG SYSTEM. EVERY PRESCRIPTION DRUG 8 ELIGIBLE FOR REIMBURSEMENT UNDER THIS ARTICLE PRESCRIBED IN RELATION TO A SERVICE PROVIDED BY THE MANAGED CARE PROVIDER SHALL BE EITHER A 9 10 PREFERRED OR NON-PREFERRED DRUG UNDER THE QUALIFIED PRESCRIPTION DRUG 11 SYSTEM. THE COMMISSIONER SHALL APPROVE A MANAGED CARE PROVIDER'S QUALI-FIED PRESCRIPTION DRUG SYSTEM IF IT CONFORMS TO THE PROVISIONS OF 12 THIS 13 SECTION.

(B) IF THE MANAGED CARE PROVIDER DOES NOT PAY FOR PRESCRIPTION DRUGS
UNDER A QUALIFIED PRESCRIPTION DRUG SYSTEM, THEN PAYMENT FOR
PRESCRIPTION DRUGS FOR THE MANAGED CARE PROVIDER'S PATIENTS SHALL NOT BE
INCLUDED IN SUCH CAPITATION PAYMENTS AND PRESCRIPTION DRUGS SHALL BE
PROVIDED FOR THE MANAGED CARE PROVIDER'S PARTICIPANTS UNDER THE
PREFERRED DRUG PROGRAM.

3. QUALIFIED PRESCRIPTION DRUG SYSTEM; CRITERIA. (A) A QUALIFIED
PRESCRIPTION DRUG SYSTEM SHALL PROMOTE ACCESS TO THE MOST EFFECTIVE
PRESCRIPTION DRUGS WHILE REDUCING THE COST OF PRESCRIPTION DRUGS UNDER
THIS ARTICLE. THIS SUBDIVISION AND SUBDIVISION FOUR OF THIS SECTION
APPLY TO QUALIFIED PRESCRIPTION DRUG SYSTEMS.

(B) WHEN A PRESCRIBER PRESCRIBES A NON-PREFERRED DRUG FOR A PARTICIPANT, REIMBURSEMENT MAY BE DENIED UNLESS PRIOR AUTHORIZATION IS
OBTAINED, UNLESS NO PRIOR AUTHORIZATION IS REQUIRED UNDER THIS SECTION.
WHEN A PRESCRIBER PRESCRIBES A PREFERRED DRUG FOR A PARTICIPANT, NO
PRIOR AUTHORIZATION SHALL BE REQUIRED FOR REIMBURSEMENT, UNLESS PRIOR
AUTHORIZATION IS REQUIRED UNDER THE CLINICAL DRUG REVIEW PROGRAM.

(C) THE COMMISSIONER SHALL ESTABLISH PERFORMANCE STANDARDS FOR SYSTEMS
 THAT, AT A MINIMUM, ENSURE THAT SYSTEMS PROVIDE SUFFICIENT TECHNICAL
 SUPPORT AND TIMELY RESPONSES TO CONSUMERS, PRESCRIBERS AND PHARMACISTS.

(D) THE COMMISSIONER SHALL ADOPT CRITERIA FOR QUALIFIED PRESCRIPTION
 DRUG SYSTEMS AFTER CONSIDERING RECOMMENDATIONS AND COMMENTS RECEIVED
 FROM PRESCRIBERS, PHARMACISTS, PARTICIPANTS, AND ORGANIZATIONS REPRES ENTING THEM.

38 (E) THE MANAGED CARE PROVIDER SHALL DEVELOP ITS PREFERRED DRUG LIST 39 BASED INITIALLY ON AN EVALUATION OF THE CLINICAL EFFECTIVENESS, SAFETY, 40 AND PATIENT OUTCOMES, FOLLOWED BY CONSIDERATION OF THE COST-EFFECTIVE-NESS OF THE DRUGS. IN EACH THERAPEUTIC CLASS, THE MANAGED CARE PROVIDER 41 SHALL DETERMINE WHETHER THERE IS ONE DRUG THAT IS SIGNIFICANTLY MORE 42 43 CLINICALLY EFFECTIVE AND SAFE, AND THAT DRUG SHALL BE INCLUDED ON THE 44 PREFERRED DRUG LIST WITHOUT CONSIDERATION OF COST. IF, AMONG TWO OR MORE 45 DRUGS IN A THERAPEUTIC CLASS, THE DIFFERENCE IN CLINICAL EFFECTIVENESS AND SAFETY IS NOT CLINICALLY SIGNIFICANT, THEN COST-EFFECTIVENESS MAY 46 47 ALSO BE CONSIDERED IN DETERMINING WHICH DRUG OR DRUGS SHALL BE INCLUDED 48 ON THE PREFERRED DRUG LIST.

49 4. PRIOR AUTHORIZATION. (A) A QUALIFIED PRESCRIPTION DRUG SYSTEM SHALL 50 MAKE AVAILABLE A TWENTY-FOUR HOUR PER DAY, SEVEN DAYS PER WEEK TELEPHONE 51 CALL CENTER THAT INCLUDES A TOLLFREE TELEPHONE LINE AND DEDICATED FACSIMILE LINE TO RESPOND TO REQUESTS FOR PRIOR AUTHORIZATION. THE CALL 52 CENTER SHALL INCLUDE QUALIFIED HEALTH CARE PROFESSIONALS WHO SHALL BE 53 54 AVAILABLE TO CONSULT WITH PRESCRIBERS CONCERNING PRESCRIPTION DRUGS THAT 55 ARE NON-PREFERRED DRUGS. A PRESCRIBER SEEKING PRIOR AUTHORIZATION SHALL 56 CONSULT WITH THE PROGRAM CALL LINE TO REASONABLY PRESENT HIS OR HER 1 JUSTIFICATION FOR THE PRESCRIPTION AND GIVE THE PROGRAM'S QUALIFIED 2 HEALTH CARE PROFESSIONAL A REASONABLE OPPORTUNITY TO RESPOND.

3 (B) WHEN A PATIENT'S HEALTH CARE PROVIDER PRESCRIBES A NON-PREFERRED 4 DRUG, THE PRESCRIBER SHALL CONSULT WITH THE SYSTEM TO CONFIRM THAT IN 5 HIS OR HER REASONABLE PROFESSIONAL JUDGMENT, THE PATIENT'S CLINICAL 6 CONDITION IS CONSISTENT WITH THE CRITERIA FOR APPROVAL OF THE NON-PRE-7 FERRED DRUG. SUCH CRITERIA SHALL INCLUDE:

8 (I) THE PREFERRED DRUG HAS BEEN TRIED BY THE PATIENT AND HAS FAILED TO 9 PRODUCE THE DESIRED HEALTH OUTCOMES;

10 (II) THE PATIENT HAS TRIED THE PREFERRED DRUG AND HAS EXPERIENCED 11 UNACCEPTABLE SIDE EFFECTS;

12 (III) THE PATIENT HAS BEEN STABILIZED ON A NON-PREFERRED DRUG AND 13 TRANSITION TO THE PREFERRED DRUG WOULD BE MEDICALLY CONTRAINDICATED; OR 14 (IV) OTHER CLINICAL INDICATIONS IDENTIFIED BY THE COMMISSIONER OR THE 15 MANAGED CARE PROVIDER FOR THE PATIENT'S USE OF THE NON-PREFERRED DRUG, 16 WHICH SHALL INCLUDE CONSIDERATION OF THE MEDICAL NEEDS OF SPECIAL POPU-17 LATIONS, INCLUDING CHILDREN, ELDERLY, CHRONICALLY ILL, PERSONS WITH 18 MENTAL HEALTH CONDITIONS, AND PERSONS AFFECTED BY HIV/AIDS OR HEPATITIS 19 C.

20 (C) IN THE EVENT THAT THE PATIENT DOES NOT MEET THE CRITERIA IN PARA-21 GRAPH (B) OF THIS SUBDIVISION, THE PRESCRIBER MAY PROVIDE ADDITIONAL 22 INFORMATION TO THE MANAGED CARE PROVIDER TO JUSTIFY THE USE OF Α NON-PREFERRED DRUG. THE SYSTEM SHALL PROVIDE A REASONABLE OPPORTUNITY 23 24 FOR A PRESCRIBER TO REASONABLY PRESENT HIS OR HER JUSTIFICATION OF PRIOR 25 AUTHORIZATION. IF, AFTER CONSULTATION WITH THE MANAGED CARE PROVIDER, PRESCRIBER, IN HIS OR HER REASONABLE PROFESSIONAL JUDGMENT, DETER-26 THE 27 THAT THE USE OF A NON-PREFERRED DRUG IS MINES WARRANTED, THE 28 PRESCRIBER'S DETERMINATION SHALL BE FINAL.

29 (D) IF A PRESCRIBER MEETS THE REQUIREMENTS OF PARAGRAPH (B) OR (C) OF 30 THIS SUBDIVISION, THE PRESCRIBER SHALL BE GRANTED PRIOR AUTHORIZATION 31 UNDER THIS SECTION.

32 IN THE INSTANCE WHERE A PRIOR AUTHORIZATION DETERMINATION IS NOT (E) 33 COMPLETED WITHIN TWENTY-FOUR HOURS OF THE ORIGINAL REQUEST, SOLELY AS THE RESULT OF A FAILURE OF THE SYSTEM (WHETHER BY ACTION OR INACTION), 34 PRIOR AUTHORIZATION SHALL BE IMMEDIATELY AND AUTOMATICALLY GRANTED WITH 35 NO FURTHER ACTION BY THE PRESCRIBER AND THE PRESCRIBER SHALL BE NOTIFIED 36 37 OF THIS DETERMINATION. IN THE INSTANCE WHERE A PRIOR AUTHORIZATION 38 DETERMINATION IS NOT COMPLETED WITHIN TWENTY-FOUR HOURS OF THE ORIGINAL REQUEST FOR ANY OTHER REASON, A SEVENTY-TWO HOUR SUPPLY OF THE MEDICA-39 40 TION SHALL BE APPROVED BY THE SYSTEM AND THE PRESCRIBER SHALL BE NOTI-41 FIED OF THIS DETERMINATION.

42 (F) WHEN, IN THE JUDGMENT OF THE PRESCRIBER OR THE PHARMACIST, AN 43 EMERGENCY CONDITION EXISTS, AND THE PRESCRIBER OR PHARMACIST NOTIFIES 44 THE MANAGED CARE PROVIDER THAT AN EMERGENCY CONDITION EXISTS, A SEVEN-45 TY-TWO HOUR EMERGENCY SUPPLY OF THE DRUG PRESCRIBED SHALL BE IMMEDIATELY 46 AUTHORIZED BY THE MANAGED CARE PROVIDER.

47 (G) IN THE EVENT THAT A PATIENT PRESENTS A PRESCRIPTION TO A PHARMA-48 CIST FOR A PRESCRIPTION DRUG THAT IS A NON-PREFERRED DRUG AND FOR WHICH 49 THE PRESCRIBER HAS NOT OBTAINED A PRIOR AUTHORIZATION, THE PHARMACIST 50 SHALL, WITHIN A PROMPT PERIOD BASED ON PROFESSIONAL JUDGMENT, NOTIFY THE 51 PRESCRIBER. THE PRESCRIBER SHALL, WITHIN A PROMPT PERIOD BASED ON PROFESSIONAL JUDGMENT, EITHER SEEK PRIOR AUTHORIZATION OR SHALL CONTACT 52 THE PHARMACIST AND AMEND OR CANCEL THE PRESCRIPTION. THE PHARMACIST 53 54 SHALL, WITHIN A PROMPT PERIOD BASED ON PROFESSIONAL JUDGMENT, NOTIFY THE 55 PATIENT WHEN PRIOR AUTHORIZATION HAS BEEN OBTAINED OR DENIED OR WHEN THE 56 PRESCRIPTION HAS BEEN AMENDED OR CANCELLED.

1 (H) ONCE PRIOR AUTHORIZATION OF A PRESCRIPTION FOR A DRUG THAT IS NOT 2 ON THE PREFERRED DRUG LIST IS OBTAINED, PRIOR AUTHORIZATION SHALL NOT BE 3 REQUIRED FOR ANY REFILL OF THE PRESCRIPTION.

4 (I) NO PRIOR AUTHORIZATION UNDER A QUALIFIED PRESCRIPTION DRUG SYSTEM 5 SHALL BE REQUIRED FOR: (I) ATYPICAL ANTI-PSYCHOTICS; (II) ANTI-DEPRES-6 SANTS; (III) ANTI-RETROVIRALS USED IN THE TREATMENT OF HIV/AIDS OR HEPA-7 TITIS C; (IV) ANTI-REJECTION DRUGS USED IN THE TREATMENT OF ORGAN AND 8 TISSUE TRANSPLANTS; AND (V) ANY OTHER THERAPEUTIC CLASS FOR THE TREAT-9 MENT OF MENTAL ILLNESS, HIV/AIDS OR HEPATITIS C, APPROVED BY THE COMMIS-10 SIONER.

5. CLINICAL DRUG REVIEW PROGRAM. IN THE CASE OF A DRUG FOR WHICH PRIOR
 AUTHORIZATION IS REQUIRED UNDER THE CLINICAL DRUG REVIEW PROGRAM, PRIOR
 AUTHORIZATION SHALL BE OBTAINED UNDER THE CLINICAL DRUG REVIEW PROGRAM
 AND NOT UNDER THIS SECTION.

15 6. PRESCRIBER CONDUCT. THE MANAGED CARE PROVIDER AND THE DEPARTMENT 16 SHALL MONITOR THE PRIOR AUTHORIZATION PROCESS UNDER A OUALIFIED 17 PRESCRIPTION DRUG SYSTEM FOR PRESCRIBING PATTERNS WHICH ARE SUSPECTED OF ENDANGERING THE HEALTH AND SAFETY OF THE PATIENT OR WHICH DEMONSTRATE A 18 19 LIKELIHOOD OF FRAUD OR ABUSE. THE MANAGED CARE PROVIDER AND THE DEPART-20 MENT SHALL TAKE ANY AND ALL ACTIONS OTHERWISE PERMITTED BY LAW TO INVES-21 TIGATE SUCH PRESCRIBING PATTERNS, TO TAKE REMEDIAL ACTION AND TO ENFORCE 22 APPLICABLE FEDERAL AND STATE LAWS.

23 7. USE OF PREFERRED DRUG PROGRAM. THE COMMISSIONER MAY CONTRACT WITH A MANAGED CARE PROVIDER FOR THE PROVIDER TO USE THE PREFERRED DRUG PROGRAM 24 25 PROVIDE PRIOR AUTHORIZATION UNDER THE MANAGED CARE PROVIDER'S QUALI-ΤO FIED PRESCRIPTION DRUG SYSTEM. THE CONTRACT SHALL INCLUDE TERMS REQUIRED 26 BY THE COMMISSIONER TO MAXIMIZE SAVINGS TO THE MEDICAID PROGRAM AND 27 PROTECT THE HEALTH AND INTERESTS OF THE MANAGED CARE PROVIDER'S PARTIC-28 IPANTS. THE CONTRACT SHALL PROVIDE WHETHER THE PREFERRED DRUG PROGRAM 29 THE MANAGED CARE PROVIDER'S LISTS OF PREFERRED AND NON-PRE-30 SHALL USE FERRED DRUGS OR THE PREFERRED DRUG LIST UNDER THE PREFERRED 31 DRUG 32 PROGRAM, WITH RESPECT TO WHETHER PRIOR AUTHORIZATION IS REQUIRED.

33 S 2. Subdivisions 25 and 25-a of section 364-j of the social services 34 law are REPEALED.

35 S 3. Subdivision 2-b of section 369-ee of the social services law is 36 REPEALED and a new subdivision 2-b is added to read as follows:

37 2-B. PAYMENT FOR PRESCRIPTION DRUGS. PAYMENT FOR PRESCRIPTION DRUGS 38 SHALL BE INCLUDED IN THE CAPITATED PAYMENTS FOR SERVICES OR SUPPLIES 39 PROVIDED UNDER A FAMILY HEALTH INSURANCE PLAN OR PROVIDED BY AN EMPLOYER 40 PARTNERSHIP FOR FAMILY HEALTH PLUS PLAN AUTHORIZED BY SECTION THREE SIXTY-NINE-EE OF THIS TITLE, PROVIDED THAT THE PLAN PAYS FOR 41 HUNDRED PRESCRIPTION DRUGS UNDER A QUALIFIED PRESCRIPTION DRUG SYSTEM UNDER 42 43 SECTION THREE HUNDRED SIXTY-FIVE-I OF THIS ARTICLE. EVERY PRESCRIPTION 44 DRUG ELIGIBLE FOR REIMBURSEMENT UNDER THIS ARTICLE PRESCRIBED IN 45 RELATION TO A SERVICE PROVIDED BY THE PLAN SHALL BE EITHER A PREFERRED OR NON-PREFERRED DRUG UNDER THE QUALIFIED PRESCRIPTION DRUG SYSTEM. 46 IF 47 DOES NOT PAY FOR PRESCRIPTION DRUGS UNDER A QUALIFIED THE PLAN PRESCRIPTION DRUG SYSTEM, THEN PAYMENT FOR PRESCRIPTION DRUGS 48 FOR THE 49 PLAN'S PATIENTS SHALL NOT BE INCLUDED IN SUCH CAPITATION PAYMENTS AND 50 PRESCRIPTION DRUGS SHALL BE PROVIDED FOR THE APPROVED ORGANIZATION'S 51 PARTICIPANTS UNDER THE PREFERRED DRUG PROGRAM.

52 S 4. Section 2511 of the public health law is amended by adding a new 53 subdivision 22 to read as follows:

54 22. PAYMENT FOR PRESCRIPTION DRUGS. PAYMENT FOR PRESCRIPTION DRUGS 55 SHALL BE INCLUDED IN THE PAYMENTS FOR SERVICES OR SUPPLIES PROVIDED BY 56 THE APPROVED ORGANIZATION, PROVIDED THAT THE PLAN PAYS FOR PRESCRIPTION

DRUGS UNDER A OUALIFIED PRESCRIPTION DRUG SYSTEM UNDER SECTION THREE 1 2 HUNDRED SIXTY-FIVE-I OF THE SOCIAL SERVICES LAW. EVERY PRESCRIPTION DRUG 3 ELIGIBLE FOR REIMBURSEMENT UNDER THIS ARTICLE PRESCRIBED IN RELATION TO 4 А SERVICE PROVIDED BY THE APPROVED ORGANIZATION SHALL BE EITHER A 5 PREFERRED OR NON-PREFERRED DRUG UNDER THE QUALIFIED PRESCRIPTION DRUG 6 SYSTEM. IF THE APPROVED ORGANIZATION DOES NOT PAY FOR PRESCRIPTION DRUGS 7 PRESCRIPTION DRUG SYSTEM, OUALIFIED THEN PAYMENT FOR UNDER Α 8 PRESCRIPTION DRUGS FOR THE APPROVED ORGANIZATION'S PATIENTS SHALL NOT BE 9 INCLUDED IN SUCH PAYMENTS AND PRESCRIPTION DRUGS SHALL BE PROVIDED FOR 10 APPROVED ORGANIZATION'S PARTICIPANTS UNDER THE PREFERRED DRUG THE 11 PROGRAM.

12 S 5. Subdivision 11 of section 270 of the public health law, as 13 amended by section 2-a of part C of chapter 58 of the laws of 2008, is 14 amended to read as follows:

15 11. "State public health plan" means the medical assistance program established by title eleven of article five of the social services law 16 17 (referred to in this article as "Medicaid"), the elderly pharmaceutical insurance coverage program established by title three of article two of 18 19 the elder law (referred to in this article as "EPIC"), [and] the family health plus program established by section three hundred sixty-nine-ee of the social services law [to the extent that section provides that the 20 21 22 program shall be subject to this article], AND THE CHILD HEALTH INSUR-ANCE PROGRAM UNDER TITLE ONE-A OF ARTICLE TWENTY-FIVE OF THIS CHAPTER. 23

24 S 6. Section 272 of the public health law is amended by adding a new 25 subdivision 12 to read as follows:

26 12. NO PRIOR AUTHORIZATION SHALL BE REQUIRED UNDER THE PREFERRED DRUG 27 PROGRAM FOR:

(A) ATYPICAL ANTI-PSYCHOTICS; (B) ANTI-DEPRESSANTS; (C) ANTI-RETROVIRALS USED IN THE TREATMENT OF HIV/AIDS OR HEPATITIS C; (D) ANTI-REJECTION DRUGS USED IN THE TREATMENT OF ORGAN AND TISSUE TRANSPLANTS; AND
(E) ANY OTHER THERAPEUTIC CLASS FOR THE TREATMENT OF MENTAL ILLNESS,
HIV/AIDS OR HEPATITIS C, RECOMMENDED BY THE BOARD AND APPROVED BY THE
COMMISSIONER UNDER THIS SECTION.

34 S 7. This act shall take effect on the one hundred eightieth day after 35 it shall become a law; provided, however, that section two of this act shall take effect one year after this act shall become a law; and 36 37 provided further, that the amendments to section 369-ee of the social services law made by section three of this act shall not affect the repeal of such section and shall be deemed to expire therewith and 38 39 40 provided further, that the commissioner of health is immediately authorized and directed to take actions necessary to implement this act when 41 it takes effect. 42